Posted by Michael Wonder on 01 Sep 2020
CADTH publishes final outcome for new medicine for patients with acquired thrombotic thrombocytopenic purpura
1 September 2020 - The CADTH Canadian Drug Expert Committee has recommended that caplacizumab not be reimbursed for the treatment of adults with acquired thrombotic thrombocytopenic purpura.
According to clinical experts consulted by CADTH, the percentage of patients who received rituximab in the pivotal clinical trial (HERCULES) was higher than what is expected in Canada. Given that 40% of patients in the overall trial period received caplacizumab in addition to rituximab (and plasma exchange and corticosteroids), it is unclear if the observed effects of caplacizumab in the trial would be observed in Canadian practice.
